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Introduction 
Candida albicans is one of the most frequent etiologic agents
causing opportunistic infections so called candidiasis, a disease
that in its systemic manifestation could prove fatal, and whose
incidence is increasing as result of an expanding population of
immunocompromised (i.e., allogenic-bone marrow transplant
recipients and HIV-infected individuals) patients [2, 42]. Despite
the efforts of numerous groups of investigators, the importance
of various virulence factors in the pathogenicity of this
microorganism remains unresolved [15]. The lack for an early
and effective diagnostic procedure, the toxicity displayed by the
most commonly used drugs to treat the infection, and the
emergence of resistant strains are causes for the high mortality
rates observed with this type of disease [39].
The cell wall is the structure that maintains the shape
characteristic for each morphology (yeast and mycelium)
displayed by C. albicans, and mediates the initial interaction
with the host [46]. Different studies have revealed the presence
of many protein and glyco(manno)protein components bound
to the cell wall in C. albicans [8, 10, 17, 43]. Among them,
mannoproteins appear to play essential roles in morphogenesis,
antigen presentation and immunomodulation, and adherence
[12, 13, 16, 32, 34].
In the last years interest has been focused in defining specific
antigenic markers for the serodiagnosis of systemic candidiasis.
A number of cytosolic candidal antigens have been described
in this context, such as enolase [51], a 47 kDa fragment of a 90
kDa heat-shock-protein (HSP90) [35–38], a 75 kDa HSP and a
non-HSP 96 kDa antigen [14], and some glycolytic enzymes [48].
However, none of them have been proven clearly to be clinically
useful. On the other hand, attempts to define cell wall-bound
antigens have shown a great variability in the antigenic
composition associated with the cell wall, depending on different
microorganism-related and environmental factors [1, 3–5, 18, 20,
29–31, 33, 44]. Besides, serological tests used to detect anti-
Candida antibodies in sera from patients have a low specificity
and sensitivity, since they mainly recognize antibodies against
Candida cell wall mannan (the carbohydrate moiety of
mannoproteins), which seem to be ubiquitous in human sera 
[23, 41, 52]. Hence, C. albicans cell wall antigens other than
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Candida albicans fibrinogen binding
mannoprotein: expression in clinical
strains and immunogenicity in
patients with candidiasis
Summary A 58 kDa cell wall-associated fibrinogen binding mannoprotein (mp58),
previously characterized by our group in a Candida albicans laboratory strain 
(ATCC 26555), was found to be also present in the cell wall of clinical isolates of
this fungus. Most strains examined appear to have functional mp58 species, as
detected by their ability to bind fibrinogen. Western immunoblot analysis, with a
monovalent polyclonal antibody generated against the mp58 species from strain
ATCC 26555, revealed differences in recognition patterns depending on the strain
tested and the culture conditions used. Serum samples from normal and Candida
infected individuals were examined for the presence of antibodies against mp58
by Western immunoblotting. None of the sera from control individuals and patients
suffering from superficial candidiasis contained antibodies against mp58. However,
positive reactivity with this antigen and other cell wall constituents was detected for
all sera from patients with confirmed systemic candidiasis. Together, these results
suggest that mp58 could play an active role during infection and may be useful as a
specific antigenic marker for candidiasis.
Key words Candida albicans · Clinical strains · Cell wall · Fibrinogen-binding
mannoprotein · Serologic response
mannan could represent potential candidates as antigenic markers.
One of the best characterized candidal cell wall components is a
58 kDa mannoprotein (mp58), which specifically interacts with
human fibrinogen [11]. The mp58 species is expressed by 
C. albicans cells in culture and in infected human tissues [11,
33], and represents a molecular entity biochemically and
functionally distinct than other C. albicans receptor-like
components, such as the C3d-receptor and the laminin binding
protein [27, 28]. In the present report we have examined the
expression of this cell wall component in different C. albicans
clinical isolates, and have investigated the presence of antibodies
against the mp58 in the sera from patients with candidiasis. Results
presented in this report support the contention that mp58 may be
(i) a putative virulence determinant, and (ii) a potential antigenic
marker for the serodiagnosis of systemic candidiasis. 
Materials and methods
Organisms and culture conditions Candida albicans ATCC
26555 and different C. albicans clinical isolates were
employed for this study (Table 1). Clinical strains were
isolated from patients with local or invasive candidiasis 
(n = 6) or from individuals colonized by the fungus (n = 11)
at Hospital Clínico, University of Valencia (Spain). Both
biochemical and serological procedures confirmed the identity
of the clinical isolates. The different strains were maintained
on 1.5% agar slopes of Sabouraud-dextrose medium. They
were propagated at 28°C as blastoconidia (yeast phase) or at
37°C under germination inducing conditions, following
basically the procedure reported previously [9] in the minimal
medium supplemented with amino acids described by 
Lee et al. [25]. 
Table 1 Candida albicans strains used
Numbera Strain identification number Isolated from
1 ATCC 26555 CMCb
2 105688 Blood
3 104851 Urine
4 104682 Blood
5 36985 Urine
6 32878 Feces
7 105671 Blood
8 24248 Blood
9 104011 Glans penis swap
10 30259 Feces
11 105719 Sputum
12 24249 Urine
13 32714 Tracheal exudate
14 32216 Gastric fluid
15 105805 Blood
16 24250 Blood
17 106203 Sputum
18 106199 Sputum
aLane number of the electrophoretic runs shown in the different panels of 
Figs. 1, 2, and 3.
bCMC, chronic mucocutaneous candidiasis.
Sera from human patients Serum samples were collected
and frozen at –70°C until they were assayed. Samples were
collected from healthy volunteers and patients admitted to the
Hospital Clínico (Valencia), and classified as follows: (i) 28
patients with confirmed systemic candidiasis, 15 of whom were
intravenous drug (heroin) abusers with cutaneous candidal
lesions and positive serial blood cultures (clinical group A) 
(9 of these patients were highly immunosuppressed, whereas
the remaining individuals developed a catheter-related
disseminated candidiasis); (ii) 46 non-hospitalized patients
suffering from superficial candidiasis (vaginitis [n = 40] and
urethritis and/or balanitis [n = 6]) (clinical group B); and (iii)
normal healthy individuals (n = 31) and hospitalized patients
with no evidence of immunosuppression, nor harboring
indwelling intravascular catheters, and not subjected to broad
spectrum antibiotics or hyperalimentation (n = 36), that is people
at low risk of developing systemic candidiasis (these individuals
showed no symptoms of either systemic or superficial
candidiasis) (clinical group C). Patients suffering invasive
candidiasis were diagnosed as such when they met one of the
following criteria: (i) repeated isolation of C. albicans from
blood (at least 3 positive blood cultures taken from separate
intravenous sites at different times) or specimens from sterile
sites; or (ii) histopathological and microbiological proof by
autopsy (necropsy) or biopsy. 
Preparation of cell wall extracts β-mercaptoethanol 
(β-ME) was used to solubilize protein and glycoprotein
components from the walls of intact cells from each C. albicans
strain grown at 28°C or 37°C, basically as has been previously
described by our group [10, 11]. The total sugar content in the
different β-ME extracts was determined colorimetrically [19]
with mannose as a standard. 
SDS–polyacrylamide gel electrophoresis (SDS–PAGE)
and Western blot techniques The cell wall-bound protein
and mannoprotein components present in the β-ME extracts
were separated by SDS–PAGE basically as described
previously [24]. Electrophoretic transfer (Western blot) to
nitrocellulose membranes (Schleicher & Schüell) was
performed by conventional methods [6, 49]. Indirect staining
of mannoproteins present in the membranes with Concanavalin
A (Con A) was performed as previously described [21, 40].
Immunodetection of blotted polypeptides was carried out using
as probe a monovalent polyclonal antibody generated against
the purified mp58 species from strain ATCC 26555 (PAb anti-
mp58) [11]. Colored reactive bands were developed as
described elsewhere [9]. Blotted proteins were assayed for
fibrinogen binding as already reported [11]. Reactivity of
human sera towards proteins and mannoproteins present in
the β-ME extracts from germinated blastoconidia of 
C. albicans ATCC 26555 strain in a Multiscreen device 
(Bio-Rad), that allow independent but simultaneous testing of
up to 16 different sera samples on the same blot. Reactive
bands were detected with a peroxidase-labeled goat anti-human
IgG (Bio-Rad). 
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Results
Expression of mp58 in clinical isolates of C. albicans
C. albicans clinical isolates recovered from different human
specimens were propagated under conditions that favor
growth as blastoconidia (28°C), or blastoconidia bearing
germ-tubes (37°C) in the reference strain (ATCC 26555).
Cells were chemically extracted by treatment with β-ME.
β-ME extracts were electrophoretically separated in 5–15%
acrylamide gradient gels. Coomassie blue staining of the
gels allowed the detection of a variety of medium-to-low
molecular mass species present in the different samples
(Fig. 1). In general, the protein patterns were similar for all
strains tested independently of the growing conditions,
though both qualitative (some moieties appeared to be
specific for a given strain) and quantitative (some other
components were found to be more abundant in the β-ME
extracts of several of the strains tested) differences were
readily discernible. A major band with an apparent
molecular weight of 58 kDa appeared to be common to all
strains and growth conditions tested, although its level of
expression appeared to vary between isolates. Indirect 
Con A-mediated peroxidase staining of nitrocellulose blots
revealed the mannoprotein nature of the 58 kDa band and
stressed the occurrence of quantitative differences in its
expression depending on the strain and the in vitro
conditions under the cells were grown (Fig. 2). 
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Fig. 1 Coomassie blue staining patterns of the polypeptides present in the 
β-ME extracts obtained from strain ATCC 26555 (lane 1) and clinical isolates
of Candida albicans (lanes 2–18; see Table 1) grown at 28°C (panel A), or
at 37°C (panel B). Samples were separated by SDS-PAGE using 5–15%
polyacrylamide gradient gels. The amount of sample applied to each well was
300 µg (expressed as total sugar contain). Arrows in both panels point to a 58
kDa polypeptide species. The electrophoretic mobility of standard proteins of
known molecular mass (mm) run in parallel is indicated to the left of both
panels, expressed in kilodalton (kDa)
Fig. 2 Characterization of mannoproteins present in β-ME obtained from strain
ATCC 26555 (lane 1) and clinical isolates of Candida albicans (lanes 2–18; see
Table 1) grown at 28°C (panel A), or at 37°C (panel B). The amount of sample
applied to each well was 100 µg (expressed as total sugar contain). Mannoproteins
were separated by SDS-PAGE (5–15% slab gradient gels), transferred to
nitrocellulose sheets, and detected with Con A-mediated peroxidase staining.
Arrows in both panels point to a 58 kDa mannoprotein. The electrophoretic
mobility (expressed in kilodalton; kDa) of standard proteins of known molecular
mass (mm) run in parallel, is indicated to the left of each panel
The possible relationship of the polypeptide species
exhibiting apparent molecular weights about 58 kDa present
in the β-ME extracts as revealed by both Coomassie blue 
(Fig. 1) and Con A-mediated peroxidase (Fig. 2) staining,
with the 58 kDa fibrinogen-binding mannoprotein (mp58)
previously characterized by our group [11], was investigated
by Western immunoblotting using the PAb anti-mp58
preparation [11], which recognizes both sugar and protein
antigenic motifs, as a probe. Cross-reactivity against PAb
anti-mp58 evidenced the presence of mp58-like species in
the clinical strains of C. albicans examined (Figs. 3A and
3C), yet differences in the reactivity towards the antiserum
were observed. Thus, although 58 kDa species were
consistently detected in the strains examined grown under
different conditions (Figs. 1 and 2), some of these species
present in β-ME extracts obtained from several strains grown
at 28°C failed to react with the PAb anti-mp58 preparation,
whereas reactivity was observed in β-ME extracts obtained
from these same strains but grown at 37°C (compare lanes
10–14 in Fig. 3A vs. Fig. 3C). The opposite situation was
also observed, since 58 kDa species in β-ME extracts from
some strains cross-reacted with the antiserum when the cells
were incubated at 28°C but not at 37°C (compare lanes 2 and
15 in Fig. 3A vs. Fig. 3C). Since PAb anti-mp58 recognize
both sugar and protein epitopes present on mp58 [11], it 
is possible that subtle differences in the regulation of 
the expression and/or in the levels of glycosylation of the
mp58-like species expressed on the surface of the C. albicans
strains tested, as a consequence of the different growing
temperatures, may account for the differences observed in
reactivity towards the antiserum.
Fibrinogen binding ability of mp58-like species
expressed by clinical isolates of C. albicans The presence
of 58 kDa moieties in β-ME extracts obtained from the
different clinical strains of C. albicans assayed in this work,
exhibiting antigenic similarity with the previously
characterized mp58 species [11], proned us to assess the
ability of such mp58-like molecules to bind fibrinogen by
means of the ligand-affinity Western blotting assay reported
elsewhere [11]. Most of the strains tested appeared to have
functional mp58-like species, as concluded by their ability
to interact with fibrinogen in the ligand-affinity experiments
(Figs. 3B and 3D). However, the presence of bands cross-
reactive with PAb anti-mp58 did not strictly correlated with
the ability of mp58-like moieties to bind fibrinogen (compare
Figs. 3A and 3C vs. Figs. 3B and 3D). Differences in ligand
binding were also observed for a given strain depending on
the in vitro growing conditions in which the cells were grown
(compare Fig. 3B vs. Fig. 3D).
Western immunoblot analysis of Candida antigens
recognized by human serum from patients suffering
invasive candidiasis The fact that most C. albicans clinical
strain examined appeared to possess mp58-like species bound
to their cell walls, led us to investigate immunogenicity
towards this/ese molecule/s in patients affected by superficial
or systemic candidiasis, to assess its potential interest as a
specific marker antigen for immunodiagnosis of candidiasis.
Blots of β-ME extracts from strain ATCC 26555 were probed
with serum samples from individuals belonging to the
different clinical groups previously established (see Materials
and methods). Some features of serum samples whose
reactivity in Western immunoblotting assays is shown in 
Fig. 4, are indicated in Table 2. Humoral immune response
of patients was currently observed against C. albicans cell
wall protein components within a molecular weight range
from >140 kDa to 20 kDa (Fig. 4, bands a–i). A 58 kDa
component (band e) along with two low molecular weight
species (<28 kDa; bands h, i), were the antigens most
frequently recognized by the sera from patients from clinical
group A, followed by antigens with molecular masses of 62
212 INTERNATL MICROBIOL Vol. 1, 1998 Sepúlveda et al.
Fig. 3 Western blotting analysis of mp58-like species present in β-ME
extracts. β-ME extracts obtained from strain ATCC 26555 (lane 1) and
clinical isolates of Candida albicans (lanes 2–18; see Table 1) grown 
at 28°C (panels A and B), or at 37°C (panels C and D) were separated by
SDS-PAGE in 5–15% slab gradient gels (the amount of sample applied to
each well, expressed as total sugar content, was 200 µg) and transferred
to nitrocellulose sheets. Blots were subsequently reacted with PAb anti-
mp58 (panels A and C) or probed with fibrinogen-anti-fibrinogen antibody
(panels B and D) (see Materials and methods). Arrows point to 58 kDa
species that exhibited reactivity following detection with PAb anti-mp58
and/or with an anti-fibrinogen antibody subsequent to incubation of the
nitrocellulose sheets in purified human fibrinogen. The electrophoretic
mobility (expressed in kilodalton; kDa) of prestained standard proteins of
known molecular mass (mm) run in parallel is indicated to the left of each
kDa (band d), and >140 kDa (bands a, b, c). Strong reactivity
with further antigens having apparent molecular weights
of 43 kDa (band f), and 38 kDa (band g) was eventually
detected with some sera (Fig. 4, lanes 1–3), yet much less
frequently. A smeared immunoreaction towards polydisperse
cell wall-bound antigens in the medium to high molecular
weight range was observed with some sera (Fig. 4, lanes 1–3,
10, 11), which eventually made very difficult to visualize
bands in the medium molecular weight range where the
mp58-like species are present. Antibodies directed against
carbohydrate immunodeterminants may account for the
recognition of such antigens, as previous adsorption of sera
with Candida mannan-coated polystyrene latex microspheres
[41] abolished immune reaction in the high molecular weight
range, yet reactivity towards the medium and low molecular
weight antigens above described (Fig. 4, bands a–i) remained
mostly unaffected (not shown). χ2 tests revealed significant
differences of frequencies of occurrence of major bands,
between the clinical group A and the control clinical group
C (P <0.005) and between clinical groups A and B (P <0.05)
(data not shown). 
Table 2 Identity and characteristics of human serum samples whose reactivity
towards antigens present in β-ME extracts is shown in Fig. 4 
Numbera Underlying condition(s) Diagnosis of candidiasis
1 AMLb, neutropenia Blood culture
2 Legionellosis, ICc Blood culture, necropsy
3 Diabetes, IC Blood culture
4 HIVd, lymphopenia Lung biopsy, blood culture
5 AML, neutropenia Blood culture, necropsy
6 Mammary carcinoma, Necropsy
autologous BMTe
7 Glioblastoma, autologous BMT Necropsy
8 Astrocytoma IV, autologous BMT Necropsy
9 SCLCf, autologous BMT Necropsy
10 Embryonary carcinoma, BMT Necropsy
11 Sarcoma, autologous BMT Necropsy
12 Superficial candidiasis Culture
13 Superficial candidiasis Culture
14 None (healthy) —
aLane number in Fig. 4; bacute myeloid leukemia; cintravascular catheter;
dhuman immunodeficiency virus; ebone marrow transplantation; fsmall cell
lung carcinoma.
Discussion
A high degree of complexity and antigenic variability in the
protein and mannoprotein components present in the cell wall
of C. albicans have been reported by several authors [10, 16,
17, 32, 43, 46]. The antigenic variability, which is considered
to be an important virulence factor, appears to be dependent
on multiple environmental- and organism-related factors 
[1, 3–5, 9, 16, 18, 20, 29–32, 44, 45, 47, 50]. 
In the present study, we have detected complex and
variable protein and mannoprotein patterns in β-ME cell wall
extracts obtained from different clinical isolates of C.
albicans. However, some components in the extracts appeared
to be expressed by most strains, among them a species with
an apparent molecular mass of 58 kDa, although quantitative
(level of expression) and qualitative (pattern of glycosylation)
variations were found between isolates depending on both
the strain and the incubation conditions used. Antigenic
(cross-reactivity with a monovalent polyclonal antiserum;
PAb anti-mp58) [11] and functional (ability to bind
fibrinogen) similarities were found between the 58 kDa
moieties present in the clinical isolates and the mp58
fibrinogen receptor previously characterized by our group
in a C. albicans reference strain (ATCC 26555) 
[11, 33]. Most strains appeared to have functional (fibrinogen-
binding) mp58-like species, although some differences in
the recognition patterns for PAb anti-mp58 and in the ability
to interact with the human ligand were detected among
isolates depending again on both the strain and the culture
conditions. Such differences could be partly attributable to
the distinct nature of the probes used for detection, since we
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Fig. 4 Western strip blots showing representative recognition patterns of
antigens present in β-ME extracts from Candida albicans germinated cells
by sera from patients with proven or strongly suspected invasive candi-
diasis, superficial candidiasis, and healthy individuals (see Table 2 for
further information). Immunoblot analysis was performed with diluted
(1:500) sera samples. Molecular mass (mm; in kilodalton, kDa) of stan-
dard molecular weight markers are indicated to the right. Letters are used
to identify the most relevant antigenic bands recognized by the different
sera (see text)
have previously described that the PAb anti-mp58 recognizes
both protein and carbohydrate antigenic motifs epitopes of
the molecule, whereas fibrinogen binding seems to occur
through the O-linked carbohydrate moiety present in the
mp58 species [11]. Thus, differences in glycosylation of 
the mp58-like species among strains may be responsible for
the differences observed. 
Expression of mp58-like species was detected in 
C. albicans strains isolated from both simply colonized hosts
and individuals affected by superficial or systemic candidiasis.
Hence, the role, if any, that these molecules may play in
pathogenesis of candidiasis remains to be determined,
although it is conceivable that they may represent a putative
fungal virulence factor. However, studies in animal models
involving the use of mutant strains lacking mp58 and of
genetic revertants in which expression of the molecule 
is restored, are required in order to establish whether mp58
and mp58-like molecules actually represent virulence
determinants in C. albicans. 
Several candidal antigens have been described as major
targets for the host immune response. These include enolase,
other glycolytic enzymes and heat-shock proteins [14, 32,
35, 38, 48, 51 ]. However, none of these have been proven
clearly to be clinically useful as specific marker antigens,
possibly due to the fact of the abundance and high levels of
homology exhibited by glycolytic enzymes and heat-shock
proteins among different pathogenic microorganisms as well
as eukaryotic organisms. Several features of mp58 led us to
assess its immunogenicity in patients with confirmed
systemic candidiasis: (i) it is highly antigenic in animals
[11], (ii) as a cell surface antigen [11] it is exposed to the
host immune system without the necessity of previous cell
lysis and processing, and (iii) it is expressed in Candida cells
colonizing infected tissues [manuscript in preparation].
Besides, preliminary cloning and sequencing data suggest
that mp58 does not show extensive homology with other
proteins whose sequence has been deposited in data bases
[1], it is present in most C. albicans strains (this work), and
is a major component in β-ME extracts. In this context, we
have previously showed that an enzyme immunoassay system
in which a mp58-containing antigenic substrate bound to the
solid phase was used, displayed a good performance in
discriminating between patients with systemic candidiasis
and individual affected by superficial infection or simply
colonized by the fungus [41]. Thus, we investigated the
presence of antibodies against the mp58 present in β-ME
extracts from mycelial cells of C. albicans ATCC 26555 in
the sera from patients suffering from candidiasis, by Western
immunoblotting. No reactivity against the mp58 was detected
when sera from either normal (control) individuals, or
patients suffering from superficial candidiasis were tested.
However, all sera from patients with confirmed systemic
infection contained antibodies against the mp58. Proteins
and mannoproteins solubilized from intact C. albicans cells
with reducing agents, i.e., dithiothreitol (DTT) or β-ME,
appear to be located in the most external layers of the cell
wall [7, 10, 16, 26] and seem to be involved in virulence-
and pathogenicity-related aspects such as adhesion to animal
tissues, interaction with serum proteins, proteolytic activities,
and cell surface hydrophobicity [7, 13, 15, 22, 26, 27]. Hence,
some of the protein and mannoprotein species present in the
β-ME extract could be expected to act as strong inductors
of the host immune response. In this context, components
of 58 and 62 kDa were two of the antigens recognized by
the sera of patients suffering invasive candidiasis in the β-
ME extracts. Besides, cell surface proteins of 60–62 kDa
that exhibited affinity for laminin and C3d have been
identified in C. albicans [7] and fibrinogen-binding
mannoprotein (characterized by our group in β-ME extracts
from intact cells of both growth forms of this fungus) has,
as already stated, a molecular mass of 58 kDa [11]. Further
characterization of other low molecular weight antigens 
(<28 kDa) that were recognized by most sera samples from
patients belonging to clinical group A (i.e., h and i in 
Fig. 4), is currently being carried out in our laboratory. In
any case, the results presented here suggest that antibodies
towards mp58 might represent a specific marker of fungal
invasiveness. 
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